Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 8:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 1,235 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Clear all

Conditions: COVID, Surgery
Interventions: Completion of pre-pandemic survey, Completion of survey after peak of pandemic, Completion of post telemedicine encounter survey; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 31 Days to 18 Years
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: SARS-CoV 2, Viral Infection, COVID 19
Interventions: Dose Finding Phase (MTD), Partially HLA-matched SARS-CoVSTs, Routine care (no SARS-CoVSTs); Biological · Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Covid19
Interventions: Ivermectin Pill, Placebo; Drug
Lead sponsor: Temple University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: COVID
Interventions: NP-120 (Ifenprodil); Drug
Lead sponsor: Algernon Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 4
States / cities: Miami, Florida • Chicago, Illinois • Saint Joseph, Missouri + 1 more

Conditions: Coronavirus Infection
Interventions: SARS-CoV-2 Antibody Analysis, Weck-cel Swab Collection, Web Based Questionnaire; Diagnostic Test · Behavioral
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 1,135 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Myocardial Injury, COVID-19, Vaccine Reaction
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Sars-CoV2
Interventions: COVID-19 PCR and Serology; Diagnostic Test
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 2
States / cities: Manhasset, New York • New Hyde Park, New York

Conditions: Healthy Participants
Interventions: REGN10933 + REGN10987, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 1 Day and older
Enrollment: 3,303 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 132
States / cities: Mesa, Arizona • Tucson, Arizona • La Mesa, California + 94 more

Conditions: COVID-19 Vaccines
Interventions: BNT162b2 Vaccine, Tdap Vaccine; Biological
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 5
States / cities: Walnut Creek, California • Miami Lakes, Florida • Honolulu, Hawaii + 2 more

Conditions: COVID-19
Interventions: nirmatrelvir, ritonavir, placebo for nirmatrelvir; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 436 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 67
States / cities: Mesa, Arizona • Phoenix, Arizona • Surprise, Arizona + 47 more

Conditions: SARS-CoV-2
Interventions: mRNA-1273; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 234 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 15
States / cities: Mesa, Arizona • San Diego, California • New Haven, Connecticut + 12 more

Conditions: Covid19
Interventions: Serologic assays for antibodies to SARS-CoV-2; Diagnostic Test
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: COVID-19
Interventions: Melatonin, Placebo; Drug
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: COVID 19 Associated Coagulopathy
Interventions: Intermediate dose thromboprophylaxis, Standard of Care thromboprophylaxis; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years to 100 Years
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Iowa City, Iowa • La Crosse, Wisconsin

Conditions: Acute Respiratory Distress Syndrome, Coronavirus, Hypoxic Respiratory Failure, Hypoxemic Respiratory Failure, Respiratory Complication, Respiratory Insufficiency, Cardiac Dysfunction, Pneumonia, Pulmonary Edema, Pulmonary Inflammation, Respiratory Failure, Cytokine Storm, COVID 19, SARS-CoV-2, Cardiac Event, Cardiac Complication, Cardiac Failure, Cardiac Infarct
Interventions: Pemziviptadil (PB1046), Low Dose (10 mg) Control; Drug
Lead sponsor: PhaseBio Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 4
States / cities: Jacksonville, Florida • Sarasota, Florida • Kansas City, Kansas + 1 more

Conditions: Renal Impairment
Interventions: PF-07321332/ritonavir; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 5
States / cities: Tustin, California • Miami, Florida • Tampa, Florida + 1 more

Conditions: SARS-CoV-2
Interventions: ACE2 Chewing Gum, Placebo Chewing Gum; Drug · Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Covid19
Interventions: Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care, Standard of care; Drug · Other
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 19 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Acute Lung Injury
Interventions: VIB7734, Placebo; Drug
Lead sponsor: Viela Bio; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Multisystem Inflammatory Syndrome in Children (MIS-C)
Interventions: Not listed
Lead sponsor: Carelon Research; Other
Eligibility: Up to 21 Years
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 32
States / cities: Tuscaloosa, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more

Conditions: COVID-19
Interventions: Ad26.COV2.S, BNT162b2, mRNA-1273, mRNA-1273.211, mRNA-1273.222, SARS-CoV-2 rS/M1; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 867 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 10
States / cities: Decatur, Georgia • Baltimore, Maryland • New York, New York + 6 more

Conditions: Covid19, SARS-CoV Infection, Communicable Disease
Interventions: Screening; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 507 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Park Ridge, Illinois

Conditions: COVID-19
Interventions: Mouth rinse; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Long COVID
Interventions: Heat therapy, Sham Control, Walking; Behavioral
Lead sponsor: University of Nebraska; Other
Eligibility: 50 Years to 90 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Omaha, Nebraska

Search by objective public record fields.

Surgical Telemedicine in the COVID-19 Pandemic Era

Anti-SARS Cov-2 T Cell Infusions for COVID 19

Outpatient Use of Ivermectin in COVID-19

Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease

SARS-CoV-2 (COVID-19) Immune Surveillance Among a Population Based Sample of Adults in Florida

Myocardial Injury and Dysfunction Associated With COVID-19 Vaccination

Incidence of COVID-19 Test Conversion in Post-surgical Patients

COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay

A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age

A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir

A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants

SARS-CoV-2 IgG and IgM Serologic Assays

Dose-Ranging Study to Assess the Safety and Efficacy of Melatonin in Outpatients Infected With COVID-19

Covid-19 Associated Coagulopathy

Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).

Renal Impairment Study of PF-07321332 Boosted With Ritonavir in Adult Participants With Renal Impairment and in Healthy Participants With Normal Renal Function.

ACE2 Chewing Gum on SARS-CoV-2 Viral Load (COVID 19)

Aggrenox To Treat Acute Covid-19

Treatment and Prevention of Acute Lung Injury (ALI) in Patients With COVID-19 Infection

Long-Term Outcomes After the Multisystem Inflammatory Syndrome in Children

Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines

COVID-19 IgG Formation in Physicians at ALGH and Their Household Members

Povidone-Iodine Oral Rinse Study

Heat thErapy And mobiLity in COVID-19 Survivors